vs
Side-by-side financial comparison of PERRIGO Co plc (PRGO) and Roper Technologies (ROP). Click either name above to swap in a different company.
Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.9× PERRIGO Co plc). Roper Technologies runs the higher net margin — 15.8% vs -127.8%, a 143.6% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs -2.5%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $148.6M). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs 1.3%).
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
PRGO vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $2.1B |
| Net Profit | $-1.4B | $331.0M |
| Gross Margin | 32.6% | 69.4% |
| Operating Margin | -116.0% | 27.2% |
| Net Margin | -127.8% | 15.8% |
| Revenue YoY | -2.5% | 11.3% |
| Net Profit YoY | -3093.9% | 53.7% |
| EPS (diluted) | $-10.23 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.1B | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $-1.4B | $428.4M | ||
| Q3 25 | $7.5M | $398.5M | ||
| Q2 25 | $-8.4M | $378.3M | ||
| Q1 25 | $-6.4M | $331.1M | ||
| Q4 24 | $-44.4M | $462.3M | ||
| Q3 24 | $-21.0M | $367.9M | ||
| Q2 24 | $-108.4M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 32.6% | 69.5% | ||
| Q3 25 | 36.1% | 69.5% | ||
| Q2 25 | 34.4% | 69.2% | ||
| Q1 25 | 37.6% | 68.7% | ||
| Q4 24 | 33.9% | 68.3% | ||
| Q3 24 | 37.2% | 69.2% | ||
| Q2 24 | 37.0% | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | -116.0% | 28.6% | ||
| Q3 25 | 7.0% | 28.4% | ||
| Q2 25 | 4.3% | 28.2% | ||
| Q1 25 | 4.5% | 27.9% | ||
| Q4 24 | 10.0% | 28.0% | ||
| Q3 24 | 7.4% | 28.1% | ||
| Q2 24 | -2.5% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | -127.8% | 20.8% | ||
| Q3 25 | 0.7% | 19.8% | ||
| Q2 25 | -0.8% | 19.5% | ||
| Q1 25 | -0.6% | 17.6% | ||
| Q4 24 | -3.9% | 24.6% | ||
| Q3 24 | -1.9% | 20.8% | ||
| Q2 24 | -10.2% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $-10.23 | $3.97 | ||
| Q3 25 | $0.05 | $3.68 | ||
| Q2 25 | $-0.06 | $3.49 | ||
| Q1 25 | $-0.05 | $3.06 | ||
| Q4 24 | $-0.32 | $4.29 | ||
| Q3 24 | $-0.15 | $3.40 | ||
| Q2 24 | $-0.79 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $382.9M |
| Total DebtLower is stronger | — | $9.7B |
| Stockholders' EquityBook value | $2.9B | $18.8B |
| Total Assets | $8.5B | $34.6B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | — | $297.4M | ||
| Q3 25 | $432.1M | $320.0M | ||
| Q2 25 | $454.2M | $242.4M | ||
| Q1 25 | $409.9M | $372.8M | ||
| Q4 24 | $558.8M | $188.2M | ||
| Q3 24 | $1.5B | $269.6M | ||
| Q2 24 | $542.8M | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $2.9B | $19.9B | ||
| Q3 25 | $4.4B | $20.0B | ||
| Q2 25 | $4.5B | $19.6B | ||
| Q1 25 | $4.4B | $19.2B | ||
| Q4 24 | $4.3B | $18.9B | ||
| Q3 24 | $4.6B | $18.5B | ||
| Q2 24 | $4.5B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $8.5B | $34.6B | ||
| Q3 25 | $10.1B | $34.6B | ||
| Q2 25 | $10.1B | $33.2B | ||
| Q1 25 | $9.8B | $31.4B | ||
| Q4 24 | $9.6B | $31.3B | ||
| Q3 24 | $11.2B | $31.6B | ||
| Q2 24 | $10.4B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.4M | — |
| Free Cash FlowOCF − Capex | $148.6M | $507.0M |
| FCF MarginFCF / Revenue | 13.4% | 24.2% |
| Capex IntensityCapex / Revenue | 2.4% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $175.4M | $738.0M | ||
| Q3 25 | $51.7M | $869.5M | ||
| Q2 25 | $75.9M | $404.1M | ||
| Q1 25 | $-64.5M | $528.7M | ||
| Q4 24 | $312.6M | $722.2M | ||
| Q3 24 | $42.2M | $755.4M | ||
| Q2 24 | $9.5M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 6.89× | 2.18× | ||
| Q2 25 | — | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
ROP
Segment breakdown not available.
